Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from Analysts at HC Wainwright

Share on StockTwits

HC Wainwright initiated coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Monday, BenzingaRatingsTable reports. The firm issued a buy rating and a $15.00 target price on the biopharmaceutical company’s stock.

ABEO has been the subject of several other reports. Mizuho downgraded shares of Abeona Therapeutics from a buy rating to a neutral rating and dropped their target price for the company from $17.00 to $4.00 in a report on Friday, July 26th. Zacks Investment Research raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research note on Tuesday, July 30th. ValuEngine raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 1st. Cantor Fitzgerald reaffirmed a buy rating and set a $29.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, May 14th. Finally, BidaskClub raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research note on Monday, June 17th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Abeona Therapeutics currently has a consensus rating of Hold and a consensus target price of $19.67.

NASDAQ:ABEO opened at $2.17 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.35 and a current ratio of 2.54. The firm has a 50-day moving average price of $3.54 and a two-hundred day moving average price of $6.08. Abeona Therapeutics has a twelve month low of $2.12 and a twelve month high of $15.65.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.13). Abeona Therapeutics had a negative net margin of 960.91% and a negative return on equity of 59.99%. On average, equities analysts anticipate that Abeona Therapeutics will post -1.74 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in ABEO. Vanguard Group Inc. boosted its stake in shares of Abeona Therapeutics by 11.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,828,699 shares of the biopharmaceutical company’s stock worth $8,742,000 after purchasing an additional 193,618 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Abeona Therapeutics by 5.9% during the 2nd quarter. BlackRock Inc. now owns 2,459,931 shares of the biopharmaceutical company’s stock worth $11,759,000 after purchasing an additional 137,558 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $196,000. Fosun International Ltd boosted its stake in shares of Abeona Therapeutics by 37.6% during the 1st quarter. Fosun International Ltd now owns 98,900 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 27,000 shares during the last quarter. Finally, Capital Fund Management S.A. acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $126,000. 63.32% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: How Does the Quiet Period Work?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.